UNSPSC 51291601: Dimetacrine

This classification denotes an antidepressant agent with the molecular formula C20H26N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O341NY501N, chemically known as 9,9-dimethyl-10-(3-(dimethylamino)propyl)acridan but generally known as dimetacrine, which bears US NIH Compound Identifier 94280. European Medicines Agency schedules Dimetacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07168MIG. The term DIMETACRINE is an International Non-Proprietary Name.

UNSPSC 51291601 Dimetacrine is a Commodity code that in practice sees little state and local procurement activity specifically aligned with its pharmaceutical scope. The recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription program development, and generic multi-source pharmaceuticals and OTC products — none of which are dimetacrine or fall within the nominal scope of this single-drug classification. The mismatch suggests that state and local procurement offices either tag pharmaceutical solicitations broadly across commodity codes without specificity to individual active ingredients, or that dimetacrine itself does not drive distinct procurement activity at the state and local level.

The three most recent opportunities show issuing bodies spanning county health agencies, state health commissions, and multi-state cooperative purchasing alliances. Seminole County, Florida issued an IFB on June 30, 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (an apparent date error in the source); the Texas Health and Human Services Commission posted an RFI on April 3, 2026 regarding direct-to-manufacturer prescription contracting; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. Activity appears concentrated in the South and Upper Midwest, though the MMCAP procurement spans multiple states including Oregon. This code does not currently show market signals that warrant pursuit based on specific dimetacrine demand.